Welcome to our dedicated page for Rein Therapeutics news (Ticker: RNTX), a resource for investors and traders seeking the latest updates and insights on Rein Therapeutics stock.
Rein Therapeutics, Inc. (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company focused on first-in-class therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications. The RNTX news feed highlights company announcements, scientific publications, regulatory updates, clinical milestones, and financing developments that shape the outlook for its pipeline.
Investors and observers can follow detailed updates on LTI-03, Rein’s lead Caveolin-1–related peptide candidate for IPF. Recent news has covered initiation and progress of the global Phase 2 RENEW trial, including first patient dosing, regulatory authorizations from the U.K. MHRA and the European Medicines Agency for sites in the United Kingdom, Germany, and Poland, and the U.S. Food and Drug Administration’s decision to lift a full clinical hold on the U.S. portion of the study.
The news stream also features translational and clinical science, such as peer-reviewed and preprint publications describing LTI-03’s anti-fibrotic activity in ex vivo lung tissue from IPF patients and inhaled dose-escalation studies assessing safety, pharmacokinetics, and biomarker changes. These reports discuss reductions in fibrosis-associated biomarkers, effects on multiple scarring pathways, and preservation of alveolar epithelial type II progenitor cells.
Additional coverage includes updates on LTI-01 for loculated pleural effusions, corporate and governance events such as annual meeting notices and adjournments, and capital markets activity, including pre-paid advance and standby equity purchase agreements and their subsequent termination. By reviewing RNTX news, readers can track how Rein Therapeutics communicates clinical progress, regulatory interactions, and strategic financing decisions that influence its development programs.
Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.
Brian Windsor, Ph.D., who serves as President and Chief Executive Officer, will deliver the presentation on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.
Interested parties can access the presentation through a live webcast at the company's investor relations website. The recording will remain available for 90 days after the event.
Rein Therapeutics (NASDAQ: RNTX) announced the acceptance of their abstract for presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentation will focus on evaluating alveolar regenerative properties of Caveolin Scaffolding Peptides (CSD) in 3D alveolospheres from IPF and normal donor lung samples.
The poster presentation (P1463) is scheduled for Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET, as part of Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.
Rein Therapeutics (NASDAQ: RNTX) has secured two new U.S. patents (No. 12,280,088 and 12,280,089) for its lead product candidate LTI-03, a synthetic peptide administered through dry powder inhalation. The patents, issued on April 22, 2025, cover both the formulation and therapeutic applications of LTI-03.
The drug features a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. It is being developed to treat various respiratory conditions including:
- Interstitial lung disease (ILD)
- Idiopathic pulmonary fibrosis (IPF)
- Chronic obstructive pulmonary disease (COPD)
- Asthma and other inflammatory or fibrotic lung conditions
The company plans to initiate a Phase 2 clinical trial of LTI-03 in IPF patients during the first half of 2025.
Rein Therapeutics (NASDAQ: RNTX) has published research in Biomedicines highlighting the therapeutic potential of their LTI-2355 peptide for treating Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F).
The study demonstrates that LTI-2355, a soluble and proteolysis-resistant 13-mer CSD peptide, improved the phagocytic activity of IPF and PASC-F myeloid cells while reducing their pro-inflammatory and pro-fibrotic synthetic activity. The research was conducted using lung explant tissue from donors and patients with IPF and PASC-F.
The manuscript was authored by Rein's leadership team, including BreAnne MacKenzie, Cory M. Hogaboam, and Brian Windsor, along with researchers from Cedars-Sinai Medical Center and Duke University.
Rein Therapeutics (NASDAQ: RNTX) has reported its Q4 and full-year 2024 financial results, highlighting progress in its lead asset LTI-03 for idiopathic pulmonary fibrosis (IPF). The company announced positive topline results from Phase 1b Cohort 2 trial, with four biomarkers achieving statistical significance and five showing dose-dependent effects.
Financial highlights include:
- Cash position of $12.9M as of December 31, 2024 (down from $17.3M in 2023)
- Q4 2024 net loss of $41.0M, including $37.0M non-cash impairment charge
- Full-year R&D expenses increased to $14.2M from $4.0M in 2023
- G&A expenses rose to $13.9M from $11.4M in 2023
The company plans to initiate a Phase 2 trial for LTI-03 in IPF during first half of 2025, subject to funding. Additionally, Rein entered an exclusive option agreement with Advancium Health Network for ALRN-6924 and completed its rebranding from Aileron Therapeutics in January 2025.
Aileron Therapeutics announced its rebranding to Rein Therapeutics, reflecting its focus on developing therapies for orphan pulmonary and fibrosis indications. The company's stock will trade under the new symbol RNTX starting January 13, 2025.
The company reported positive topline data from Cohort 2 of its Phase 1b trial for LTI-03 in November 2024, showing statistical significance in four biomarkers and dose dependence in five markers for idiopathic pulmonary fibrosis (IPF) treatment. The high-dose LTI-03 (5 mg BID) demonstrated a favorable safety profile.
In 2024, Brian Windsor was appointed CEO, and the company raised $17.7 million through a stock offering. For 2025, Rein plans to initiate a Phase 2 trial for LTI-03 in IPF treatment. The company also has LTI-01, a Phase 2b-ready asset for loculated pleural effusions, which has received Orphan Drug and Fast Track Designations.